Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Immunological Methods|October 10, 2023
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfaXiaoyun Yang, Ketevan Siradze, Gizette Sperinde, et al.
Cancer Treatment and Research Communications|September 13, 2018
A novel algorithm to improve specificity in ovarian cancer detectionAudrey Arjomandi, Michelle L Delanoy, Roger P Walker, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 8, 2026
Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic ConditionsFei Tang, Steve Dang, Audrey Arjomandi, et al.
Reproductive Toxicology (Elmsford, N.Y.)|December 23, 2023
Repeat-dose and embryo-fetal developmental toxicity of zinpentraxin alfaGautham K Rao, Sara F Santagostino, Lisa Wong, et al.
The AAPS Journal|January 24, 2024
Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology StudiesAudrey Arjomandi, Ketevan Siradze, Melissa Cheu, et al.
The AAPS Journal|December 19, 2023
Novel Selective Quantification of Zinpentraxin Alfa Biotherapeutic in the Presence of Endogenous Isomer in Plasma Samples of Idiopathic Pulmonary Fibrosis Patients Using Immunoaffinity LC-MSMaoyin Li, Audrey Arjomandi, Xiaowei Sun, et al.
Clinical and Translational Science|October 2, 2025
Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical StudiesWenhui Zhang, Dorothy Cheung, Alice Fong, et al.
Clinical Pharmacology in Drug Development|April 23, 2024
Comparative Pharmacokinetics and Safety Assessment of 1st- and 2nd-Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover StudyTu H Mai, Rajbharan Yadav, Audrey Arjomandi, et al.
Lupus Science & Medicine|June 17, 2026
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosusElsa Martins, Vishala L Chindalore, X Rebecca Sheng, et al.
Pageof 1